Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS)
CNY 87.32
(3.15%)
CNY 87.32
(3.15%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 696.61 Million CNY | 391.99% |
| 2022 | 153.38 Million CNY | 4144.47% |
| 2021 | 44.62 Million CNY | 99.03% |
| 2020 | -296.82 Million CNY | 20.58% |
| 2019 | -380.15 Million CNY | -346.06% |
| 2018 | -86.28 Million CNY | -188.28% |
| 2017 | -30.51 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 478.96 Million CNY | 17.33% |
| 2024 Q1 | 311.61 Million CNY | 30.96% |
| 2024 Q2 | 387.74 Million CNY | 30.04% |
| 2023 Q3 | 201.99 Million CNY | 15.06% |
| 2023 FY | - CNY | 391.99% |
| 2023 Q4 | 200.9 Million CNY | -0.54% |
| 2023 Q2 | 175.55 Million CNY | 527.29% |
| 2023 Q1 | 27.98 Million CNY | -56.69% |
| 2022 Q3 | 17.83 Million CNY | -59.17% |
| 2022 Q2 | 43.67 Million CNY | 238.75% |
| 2022 Q1 | -31.47 Million CNY | 74.76% |
| 2022 FY | - CNY | 4144.47% |
| 2022 Q4 | 64.61 Million CNY | 262.32% |
| 2021 Q2 | -45.34 Million CNY | 21.04% |
| 2021 Q4 | -124.69 Million CNY | -162.02% |
| 2021 FY | - CNY | 99.03% |
| 2021 Q1 | -57.43 Million CNY | 44.84% |
| 2021 Q3 | 201.05 Million CNY | 543.34% |
| 2020 Q3 | -68.87 Million CNY | 65.29% |
| 2020 FY | - CNY | 20.58% |
| 2020 Q2 | -198.41 Million CNY | -401.92% |
| 2020 Q1 | 65.71 Million CNY | 145.05% |
| 2020 Q4 | -104.12 Million CNY | -51.19% |
| 2019 Q1 | 164.54 Million CNY | 0.0% |
| 2019 Q3 | -38 Million CNY | 76.86% |
| 2019 Q4 | -145.88 Million CNY | -283.85% |
| 2019 FY | - CNY | -346.06% |
| 2019 Q2 | -164.24 Million CNY | -199.82% |
| 2018 FY | - CNY | -188.28% |
| 2017 FY | - CNY | 0.0% |